Sk Biopharmaceuticals Co Ltd (326030) — Cash Flow Reinvestment Rate
Sk Biopharmaceuticals Co Ltd (326030) has a Cash Flow Reinvestment Rate of 0.33x as of December 2025, reinvesting ₩28.92 Billion (capex ₩26.55 Billion plus investments ₩-2.37 Billion) from operating cash flow of ₩87.00 Billion. Check 326030 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Sk Biopharmaceuticals Co Ltd Cash Flow Reinvestment Rate (2024–2025)
Historical reinvestment intensity for Sk Biopharmaceuticals Co Ltd across 2 annual periods. Explore cash flow to debt ratio of Sk Biopharmaceuticals Co Ltd to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Sk Biopharmaceuticals Co Ltd (2024–2025)
Year-by-year capital reinvestment analysis for Sk Biopharmaceuticals Co Ltd. For live market cap and broader valuation context, see 326030 stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.19x | ₩33.88 Billion | ₩176.33 Billion | ₩29.51 Billion | ▲ +7.7% |
| 2024 | 0.18x | ₩16.93 Billion | ₩94.90 Billion | ₩13.42 Billion | — |